Infusion Therapy Picking up More Investor Cash as Oak HC/FT Backs Provider’s $50M Funding Round

Infusion for Health, a network of ambulatory infusion centers, picked up $50 million in funding to accelerate its expansion into new markets. The fast-growing company, based in Thousand Oaks, California, is focused on developing offerings that enable its infusion centers to engage both patients and providers earlier in the care process, the company said in a press release. There is a growing market of outpatient infusion centers that offer an alternative to receiving services at a hospital infusion center or oncology clinic. Many of these companies aim to differentiate themselves by providing a more consumer-centric approach with modern clinics that feature perks like comfortable, private suites with oversized leather recliners and on-demand entertainment.

Option Care Health Acquires Infinity Infusion Nursing, LLC

Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services in the United States, announced today that it has acquired Infinity Infusion Nursing, LLC (“Infinity”). Infinity is a leader in home infusion services that provide therapy management for patients with acute, chronic and rare disorders through a national network of highly-skilled, specialty nurses.

Acon Investments’ BioMatrix Is up for Sale

A sale process has kicked off for BioMatrix, a private equity-backed national provider of specialty pharmacy and home infusion services, according to four sources familiar with the matter. Cantor Fitzgerald is running the process, which is in its early stages, sources said. ACON Investments, a Washington, DC-based international mid-market private equity firm, completed its acquisition of BioMatrix in November 2016.

Option Care Hungry for M&A

With a tuck-in acquisition in the Southeast, a new state-of-the-art facility in Chicago and new therapies added to its chronic care portfolio, Option Care Health is laying the groundwork for sustainable growth, say company officials. Option Care announced May 6 it had paid $18.5 million for Houston-based BioCureRx, a regional provider of certain chronic care therapies. “While limited in size, the BioCure transaction signifies our appetite to become more active on the M&A front,” said Mike Shapiro, CFO, on a recent earnings call.

HealthEdge Completes Investment in Specialty Pharmacy Nursing Network

HealthEdge Investment Partners, LLC (“HealthEdge”), a healthcare focused private equity fund, announced that it has completed an investment in Specialty Pharmacy Nursing Network, Inc. (“SPNN”), a national provider of specialty home infusion nursing services. Through its national network of highly trained infusion nurses, SPNN provides outsourced solutions to specialty pharmacies and biopharmaceutical manufacturers for drug administration, patient education and training, clinical call support, and patient outcome reporting. SPNN specializes in serving patients with rare, chronic, and orphan disorders.

Sale Process Underway for Halifax-Backed PromptCare

The Halifax Group’s PromptCare, composed of a complex respiratory business and a infusion-therapy business, is on the auction block, four sources told PE Hub. Sources said the process could result in two transactions for PromptCare, which has two very distinct businesses under the same umbrella: an in-home infusion-therapy business and a complex respiratory business.

PromptCare Acquires NBN Infusions, Inc.

The PromptCare Companies (“PromptCare” or the “Company”), a leading regional provider of complex respiratory and specialty home infusion services, announced it has acquired substantially all of the assets of NBN Infusions, Inc. (“NBN”) from its founder, Linda Begley. The acquisition will further expand PromptCare’s footprint in the Northeastern United States. Founded in 1990, NBN is a Cherry Hill, NJ-based provider of home infusion and respiratory therapy services with a primary focus on managing specialty infusion therapies for patients with complex and chronic conditions.

RiverGlade Capital Announces New Partnership with Dynamic Infusion Therapy

RiverGlade Capital (“RiverGlade”), a healthcare services-focused private equity firm, has formed a new partnership with Dynamic Infusion Therapy, LLC (“DIT” or the “Company”), a full-service, on-demand outsourced provider of vascular access insertion services with a proven clinical model that lowers costs for its customers and leads to better patient outcomes.Based in Plano, TX, DIT is the largest outsourced provider of vascular access insertions, serving more than 700 health systems and hospitals, long term acute care facilities, nursing homes and other healthcare providers.

Linden Invests in Vital Care

Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, announced a majority investment in Vital Care, Inc. (“Vital Care” or the “Company”) alongside current shareholders (the Bell family) and management. Founded in 1986 and headquartered in Meridian, Mississippi, Vital Care is the premier franchisor of home infusion services, with franchises serving a wide range of patients including those with chronic conditions as well as acute conditions. The Company supports over 50 franchises across 20 states with a focus on the underserved secondary markets.

IVX Health Completes Acquisition of Precision Healthcare

IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis, announced Wednesday its acquisition of Precision Healthcare, formerly a subsidiary of BAI Healthcare Services, Inc. Based in Nashville, Tenn., Precision operates 12 infusion centers across Tennessee and northern Arkansas. The acquisition financing was led by a preferred equity investment from Linden Capital Partners – a Chicago-based private equity firm focused exclusively on the healthcare sector – and joined by existing institutional investors McKesson Ventures, Health Velocity Capital, and Nueterra Capital.